In this study, blood concentrations of the chemokine IFN-γ–induced protein 10 (IP10; C-X-C motif chemokine ligand 10 [CXCL10]), which is induced by IFN-γ, were decreased at week 24 in patients receiving ritlecitinib; additionally, infiltration of inflammatory CD8+ and NKG2D+ T cells was reduced at the level of individual HFs (190). This evidence concerns the gene CD8A and Hand-foot syndrome.